908 Devices (NASDAQ:MASS – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.16) per share and revenue of $18.31 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.
908 Devices (NASDAQ:MASS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. The firm had revenue of $16.07 million during the quarter, compared to analysts’ expectations of $15.37 million. On average, analysts expect 908 Devices to post ($0.59) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.
908 Devices Trading Up 5.9%
Shares of MASS traded up $0.61 during mid-day trading on Tuesday, hitting $10.82. 51,776 shares of the company traded hands, compared to its average volume of 336,429. The stock has a market capitalization of $447.11 million, a price-to-earnings ratio of -11.39 and a beta of 0.63. The business has a 50-day moving average of $11.21 and a 200 day moving average of $8.38. 908 Devices has a one year low of $5.03 and a one year high of $13.35.
Analyst Ratings Changes
Several equities analysts have recently issued reports on MASS shares. Stifel Nicolaus upped their price target on 908 Devices from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group started coverage on 908 Devices in a research report on Thursday, September 10th. They issued a “buy” rating and a $13.50 price objective for the company. Roth Capital boosted their price objective on 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research report on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $12.83.
Read Our Latest Report on MASS
Insider Buying and Selling at 908 Devices
In other news, Director Christopher Brown sold 30,000 shares of the firm’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $11.89, for a total value of $356,700.00. Following the transaction, the director directly owned 745,559 shares in the company, valued at $8,864,696.51. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 5,257 shares of 908 Devices stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $10.22, for a total value of $53,726.54. Following the sale, the senior vice president directly owned 57,784 shares of the company’s stock, valued at approximately $590,552.48. This trade represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 141,915 shares of company stock worth $1,477,002. Insiders own 28.20% of the company’s stock.
908 Devices Company Profile
908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions.
The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.
Featured Articles
- Five stocks we like better than 908 Devices
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
